I
Ilona Kocáková
Publications - 47
Citations - 4798
Ilona Kocáková is an academic researcher. The author has contributed to research in topics: Colorectal cancer & Panitumumab. The author has an hindex of 13, co-authored 46 publications receiving 4343 citations.
Papers
More filters
Journal ArticleDOI
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
Jean-Yves Douillard,Kelly S. Oliner,Salvatore Siena,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Richard Thomas Williams,Alan Rong,Jeffrey Wiezorek,Roger Sidhu,Scott D. Patterson +21 more
TL;DR: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2.
Journal ArticleDOI
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard,Salvatore Siena,Jim Cassidy,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Kelly S. Oliner,Michael S. Wolf,Jennifer Gansert +19 more
TL;DR: This study demonstrated that panitumumab-FOLFOX4 was well tolerated and significantly improved PFS in patients with WT KRAS tumors and underscores the importance of KRAS testing for patients with mCRC.
Journal ArticleDOI
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
Jean-Yves Douillard,Salvatore Siena,Jim Cassidy,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Kelly S. Oliner,Ying Tian,F. Xu,Roger Sidhu +20 more
TL;DR: In WT KRAS mCRC, PFS was improved, objective response was higher, and there was a trend toward improved OS with panitumumab-FOLFOX4, with significant improvement in OS observed in an updated analysis of survival.
Journal ArticleDOI
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
Hans-Joachim Schmoll,David Cunningham,Alberto Sobrero,Christos S. Karapetis,Philippe Rougier,Sheryl Koski,Ilona Kocáková,Igor Bondarenko,Gyoergy Bodoky,Paul N. Mainwaring,Ramon Salazar,Peter Barker,Bijoyesh Mookerjee,Jane Robertson,Eric Van Cutsem +14 more
TL;DR: Cediranib activity, in terms of PFS and OS, was comparable to that of bevacizumab when added to mFOLFOX6; however, the predefined boundary for PFS noninferiority was not met.
Journal ArticleDOI
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
Marek Svoboda,Jiri Sana,Pavel Fabian,Ilona Kocáková,Jana Gombošová,Jana Nekvindová,Lenka Radová,Rostislav Vyzula,Ondrej Slaby +8 more
TL;DR: This pilot study suggests that miRNAs are part of the mechanisms that are involved in response of rectal cancer to the chemoradiotherapy and that mi RNAs may be promising predictive biomarkers for such patients.